<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35504315</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-2968</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>201</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biochemical pharmacology</Title>
          <ISOAbbreviation>Biochem Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Can GABAkines quiet the noise? The GABA<sub>A</sub> receptor neurobiology and pharmacology of tinnitus.</ArticleTitle>
        <Pagination>
          <StartPage>115067</StartPage>
          <MedlinePgn>115067</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2022.115067</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0006-2952(22)00161-7</ELocationID>
        <Abstract>
          <AbstractText>Tinnitus is a highly prevalent and disabling disorder in which sound is perceived in the absence of an external auditory energy source. The disorder is complex and can arise from multiple etiologies. Co-morbid symptoms of anxiety, depression, and sleep loss are prevalent. There are no approved medications and the treatments that have been studied produce marginal improvements in symptoms. A major hypothesis of the etiology and maintenance of tinnitus is that inhibitory input mechanisms become compromised where impaired γ-aminobutyric acid (GABA) synaptic transmission has been implicated. This general idea lends support to the potential for enhanced inhibition by drugs that enhance GABA function (GABAkines) to dampen symptoms of tinnitus. Convergent evidence from neurochemical, anatomical, physiological, and pharmacological studies support the GABA<sub>A</sub> hypothesis. Although there is surprising a relatively sparse data set, examples of therapeutic efficacy have been reported with GABAkines. These studies have relied primarily on classical benzodiazepine anxiolytics like alprazolam and clonazepam. However, the possibility that novel GABAkines with unique activities might be effective have yet to be intensively explored. For example, data implicating extrasynaptic GABA<sub>A</sub>receptors in the control of tinnitus suggests the potential for extrasynaptic GABA<sub>A</sub> receptor modulators. The large medical need, a basis for further testing of the GABA<sub>A</sub> hypothesis, and the recent reinvigoration of the drug development pipeline of new GABAkines, combine to give impetus and promise for further inquiry.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Witkin</LastName>
            <ForeName>Jeffrey M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>RespireRx Pharmaceuticals Inc, Glen Rock, NJ, USA; Department of Chemistry &amp; Biochemistry, Milwaukee Institute of Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, USA; Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, INpolis, IN, USA. Electronic address: witkinconsult@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lippa</LastName>
            <ForeName>Arnold</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>RespireRx Pharmaceuticals Inc, Glen Rock, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Jodi L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, INpolis, IN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cook</LastName>
            <ForeName>James M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>RespireRx Pharmaceuticals Inc, Glen Rock, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cerne</LastName>
            <ForeName>Rok</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>RespireRx Pharmaceuticals Inc, Glen Rock, NJ, USA; Laboratory of Antiepileptic Drug Discovery, Ascension St. Vincent, INpolis, IN, USA; Department of Anatomy and Cell Biology, Indiana University/Purdue University, Indianapolis, IN, USA; Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, Ljubljana, Slovenia. Electronic address: rok_cerne@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Biochem Pharmacol</MedlineTA>
        <NlmUniqueID>0101032</NlmUniqueID>
        <ISSNLinking>0006-2952</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>19</Hour>
          <Minute>23</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35504315</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bcp.2022.115067</ArticleId>
        <ArticleId IdType="pii">S0006-2952(22)00161-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
